Pfizer's Lyrica fails in postmarketing study; Gilead sales of hep C drugs may surprise;

@FiercePharma: Mylan recalls drug after problem uncovered with Indian supplier. FiercePharmaManufacturing article | Follow @FiercePharma

@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Glaxo to reap $890M as it halves stake in South Africa's Aspen. Story | Follow @CarlyHFierce

> Pfizer's ($PFE) blockbuster pain drug Lyrica failed a postmarketing study testing the treatment in adolescents with fibromyalgia; the drug is already approved to treat the condition in adults. Report

> New IMS data shows total prescriptions of Gilead Sciences' ($GILD) hepatitis-C treatments growing by 2.1% last week leading ISI analyst Mark Schoenebaum to think its first-quarter sales could surprise to the upside. Blog

> The Lebanese health minister filed lawsuits against Pfizer and Mectapharm, a distributor, for overcharging the state for medication used to treat Parkinson's disease. Story

Medical Device News

@FierceMedDev: 23andMe launches new therapeutics group with biotech vet taking the reins. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA calls for panel meeting to discuss devices linked to superbug outbreak. Article | Follow @EmilyWFierce

> Zimmer recalls part of Persona--a total knee replacement that helped drive 2014 growth. More

> Medtronic launches U.S. clinical trial of its newest drug-eluting stent. Article

Biotech News

@FierceBiotech: EuroBiotech: Sanofi backs immunotherapy hub, U.K. mulls its own 'breakthrough,' Allergy player banks £20M. Report | Follow @FierceBiotech

@JohnCFierce: Coming up on 500 responses to our survey question: Sustainable bull market or biotech bubble? Let's hear from you. Survey | Follow @JohnCFierce

@DamianFierce: Science RT @NYTArchives: An unlucky kitten is volunteered to test weightlessness inside an F-94C at 25,000 feet, 1958. Picture | Follow @DamianFierce

> Biogen Idec trims R&D staff, looks for new talent in chemistry, neurology. More

> Third Rock's faded Ember gets resuscitated in merger deal. Report

 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.